Dubai: Covaris Inc., signed an exclusive distribution agreement with Alliance Global to bring their tools and technologies for pre-analytical sample preparation to the markets of Middle East, Africa and parts of Central Asia.
Covaris Focused-ultrasonicators are engineered to deliver highly-controlled and focused acoustic energy to samples in a temperature-controlled and non-contact environment. Focused-ultrasonicators standardize sample preparation for a variety of application areas that include DNA shearing for Next-Generation Sequencing, RNA and protein extraction, chromatin shearing, cell lysis, tissue to biomarker, compound management, formulations, and more.
“Covaris fits perfectly into the Genomics portfolio at Alliance Global, allowing us to offer a complete solution to our customers” said Althea Fernandes, Product Manager for the Genomics division at Alliance Global Group.
The range of Focused-ultrasonicators available covers sample preparation needs from high throughout batch processing to benchtop units, facilitating AGBL to not only serve high volume biomedical laboratories, but smaller laboratories as well.
“Alliance Global brings unique commercial advantages to the Middle East and Africa markets, and we are excited to be working with them to bring innovative solutions to their customers” said Guillaume Durin, General Manager at Covaris Ltd.
-Ends-
About Covaris
Covaris is dedicated to accelerating discoveries in life sciences and bioanalysis by developing “best practices” sample preparation tools. By combining its proprietary Adaptive Focused Acoustics® (AFA®) technology with aqueous reagents, patented Focused-ultrasonicators, and high-throughput workflows, Covaris has revolutionized bioanalytical applications. AFA-energetics® is the gold standard for shearing DNA and RNA for Next Generation Sequencing (NGS) and is setting new standards in FFPE-related DNA/RNA/protein extraction, cfDNA extraction, epigenomics, proteomics, and cell lysis. Thousands of Focused-ultrasonicators are in use in over 30 countries and customers include the world's leading researchers, universities, and pharmaceutical companies.
For more information, please visit: www.covaris.com
About Alliance Global Group (AGBL)
The AGBL Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group’s stated mission is to improve the lives of the region’s inhabitants through novel biomedical technologies and products.
For more information, please visit: www.agbl.net
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
